Epstein-Barr virus infection can engender severe B-cell lymphoproliferative disorders in immunocompromised individuals. In immunocompetent […]
Tumour-specific molecular targets and alternative therapeutic strategies for triplenegative breast cancer (TNBC) are urgently needed. The protease […]
The present invention relates to the adoptive therapy using notably CAR-T cells. Herethe inventors used a lentiviral vector approach to silence RINF […]
In ovarian carcinoma, Müllerian Inhibiting Substance (MIS) type II receptor (MISRII) and the MIS/MISRII signaling pathway are potential therapeutic […]
The invention relates to a bispecific antibody targeting TfR1 and a soluble antigen. The inventors demonstrate that the unique mode of interaction of […]
CAR macrophages (CAR-M) can phagocyte tumor cells expressing a target antigen. It is herein shown that the proprotein convertase furin is […]
Chimeric proteins for cancer immunotherapy can combine different activities bydisplaying both agonistic and antagonistic properties on a single […]
The invention relates to peptides derived from the MELOE antigen for therapeutic vaccination against cancer. A phase I clinical trial for ex-vivo […]
The present invention relates to a method for treating an infection, particularly HCMV infection. To date, there are very few reports on the role of […]
The present invention relates to polypeptide for engineering integrase chimeric proteins and their use in gene therapy. A key challenge for gene […]